Immuneering Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 8.49K shares, a 429.11% increase year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 4.70K shares.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 87.23K shares.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 47.22K shares.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 136.06K shares, a 40.66% decline from fiscal 2024.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 229.30K shares, a 82.53% increase from fiscal 2023.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 125.62K shares, a 27.49% increase from fiscal 2022.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 98.53K shares, a 16.39% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 8.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 147.64K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 4.70K shares 10-Q · filed 2026-05-15 | 140.76K shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 87.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | 136.06K shares 10-K · filed 2026-03-06 |
| 2025-09-30 | 47.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 48.83K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 1.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 1.60K shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-05 | 0.00 shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 229.30K shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 231.81K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 237.90K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 229.30K shares 10-Q · filed 2024-05-07 | 277.86K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 2.51K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | 125.62K shares 10-K · filed 2024-03-01 |
| 2023-09-30 | 6.09K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 137.12K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 39.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 143.46K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 77.06K shares 10-Q · filed 2023-05-04 | 112.50K shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 14.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 98.53K shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 12.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 87.03K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 9.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 172.45K shares derived: sum of 4 quarters · filed 2022-08-10 |
| 2022-03-31 | 63.10K shares 10-Q · filed 2022-05-10 | |
| 2021-12-31 | 2.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 117.85K shares 10-K · filed 2022-03-10 |
| 2021-09-30 | 97.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |